Abstract:Lung cancer is the leading cause of death worldwide with a high metastasis rate. Non-small cell lung cancer accounts for 75-85% of lung cancers. Growing evidences show that some, if not all, tumors derive from a minor subpopulation of cancer cells, also known as cancer stem-like cells (CSCs), either retain or acquire the capacity for self-renewal and drug resistance. By the virtue of altered cell signaling pathways related to cell survival and/or apoptosis, CSCs are able to survive radiation or chemotherapeutic insults. Thus, the targeting of key signaling pathway(s) that is active in CSCs is very attractive therapeutic strategy to treating cancers. However, research has been hampered due to the lack of distinct molecular makers on CSCs. We take advantage of a rare subset of cells that can efflux the DNA binding dye out of the cell. These cells, called side population (SP) cells, are proved to be enriched with CSCs and have stem cell characteristics. We evaluated the existence of SPs in PC-9 cells by staining them with Hoechst 33342. SP cells occupied 0.6-2.4% of the total cells in PC-9 cultures. It was noteworthy that the SP was completely eliminated in the presence of Verapamil. Consistent with our hypothesis that EGFR-TKIs regulate CSC, constitutive activation of EGFR increased the subpopulation almost 4.5-fold to 4.0%, whereas EGFR-TKI almost completely ablated it resulting in only 0.2% or 0.3% of the total cells. To understand the molecular mechanism(s) that EGF promote CSC population, the phosphorylation of EGFR at Tyr1068, AKT at Ser473 and ERK at Thr202/Tyr204 were investigated and they are all positive. More interestingly, EGFR/PI3K/AKT signaling inhibitors including Gefitinib, LY294002, U0126 and Erlotinib, significantly reduced the stem-like cancer cells. These results strongly suggested the importance of EGFR/PI3K/AKT as a potential target of eliminating CSCs. To verify that the effect of EGFR-TKIs on CSC phenotypes is mediated through β-catenin signaling, we used CSC-specific siRNAs to suppress β-catenin expression in PC-9 cells. A significant decrease in cancer stem-like cells was observed following β-catenin suppression. The treatment with Gefitinib dramatically reduced the tumor numbers and size in vivo xenograft model with PC9 cells. Although there were few SP cells (1.3% as detected) in Gefitinib-treated mice in the primary tumors, more discernible numbers of SP cells were detected in Cisplatin-treated (13.6%) or control-treated tumors (8.3%). Most notably, the reduction of SP cells by Gefitinib significantly reduced the migration capability. As a comparison, those primary culture cells derived from Cisplatin-treated tumors had an increased migration rate. Our discoveries raise an intriguing question of the role of β-catenin in acquired resistance of EGFR-TKIs-treated cancer stem cell-like population(s) and its potential as new treatment strategy for NSCLC in the future. Citation Format: Fan Yang, Jiacong You, Yang Li, Jiayu Liao, Qinghua Zhou. Cancer stem cell-like population from non-small cell lung cancer is preferentially suppressed by EGFR-TKIs. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3741. doi:10.1158/1538-7445.AM2013-3741

Spred-3 Mutation and Ras/Raf/MAPK Activation Confer Acquired Resistance to EGFR Tyrosine Kinase Inhibitor in an EGFR Mutated NSCLC Cell Line.

Spred2 is involved in imatinib-induced cytotoxicity in chronic myeloid leukemia cells

Long Non-Coding RNA BC087858 Induces Non-T790m Mutation Acquired Resistance to EGFR-TKIs by Activating PI3K/AKT and MEK/ERK Pathways and EMT in Non-Small-cell Lung Cancer

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Regulation of Human Hepatocellular Carcinoma Cells by Spred2 and Correlative Studies on Its Mechanism.

Spred2 Inhibits Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Impairing ERK Signaling

Molecular Mechanism of Acquired Drug Resistance in the EGFR‐TKI Resistant Cell Line HCC827‐TR

Abstract 5868: Upregulation of HER3 and MET in non-small cell lung cancer cells resistant to EGFR tyrosine kinase inhibitor

P70s6k Promotes Acquired Resistance of Erlotinib Through Induction of Epithelial-Mesenchymal Transition in Non-Small Cell Lung Carcinoma.

Abstract 3741: Cancer Stem Cell-Like Population from Non-Small Cell Lung Cancer is Preferentially Suppressed by EGFR-TKIs.

Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells.

Tyrosines 303/343/353 Within the Sprouty-related Domain of Spred2 Are Essential for Its Interaction with P85 and Inhibitory Effect on Ras/ERK Activation

The Mir‑625‑3p/axl Axis Induces Non‑t790m Acquired Resistance to EGFR‑TKI Via Activation of the TGF‑β/Smad Pathway and EMT in EGFR‑mutant Non‑small Cell Lung Cancer.

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

Spred1 Deficit Promotes Treatment Resistance and Transformation of Chronic Phase CML

Shp2 Regulates Migratory Behavior and Response to EGFR-TKIs Through ERK1/2 Pathway Activation in Non-Small Cell Lung Cancer Cells

Estrogen Receptor Β1 Activation Accelerates Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Stratification of Non-Small Cell Lung Adenocarcinoma Patients with EGFR Actionable Mutations Based on Drug-Resistant Stem Cell Genes

Aberrant Epidermal Growth Factor Receptor Signaling And Enhanced Sensitivity To Egfr Inhibitors In Lung Cancer

PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling

Abstract 5839: Identification of low-dose ligand dependent drug-resistance in ALK/ROS1 positive NSCLC via CRISPR library screening